Zydelig™

Read the CMI leaflet (Opens in new tab) for facts you need to know before, during and after taking your medicine.

For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).

ZYDELIG in combination with rituximab is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL) upon relapse in patients for whom chemo-immunotherapy is not considered suitable. ZYDELIG in combination with ofatumumab is indicated for the treatment of adult patients with CLL/SLL upon relapse in patients for whom chemo-immunotherapy is not considered suitable. ZYDELIG is indicated as monotherapy for the treatment of patients with follicular lymphoma which is refractory to at least two prior systemic therapies. The disease must be refractory to both rituximab and an alkylating agent.

Source: ARTG

• Shelf lifetime is 60 Months
• Store below 30 degrees Celsius
• Store at room temperature

Source: ARTG

Non-composite pack

This medicine contains one component only.

Component

• Tablet, film coated
• Oral
• Each 100 mg ZYDELIG tablet is oval-shaped, film-coated and orange in colour. Each tablet is debossed with GSI on one side and 100 on the other.

Source: ARTG

These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4: Prescription Only Medicine.?What is the medicines and poisons schedule?

All medicines and poisons in Australia are categorised by how they are made available to the public. Medicines with a low safety risk are usually less tightly controlled than medicines with a higher safety risk. This system is called ‘scheduling’. You can read more about the scheduling of medicines as well as the different scheduling categories on our Scheduling of medicines and poisons information page.

• 60 Tablets, Bottle

Source: ARTG

This medicine was verified as available on the Pharmaceutical Benefits Scheme (PBS) on 1 August 2026, under the following PBS item codes:

• 11170X (Opens in new tab)
• 12813J (Opens in new tab)
• 11171Y (Opens in new tab)

Ask your pharmacist or doctor about your eligibility

Source: PBS

For the active ingredient: idelalisib

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

Source: AHT

If you experience a side effect from this medicine, tell your doctor or pharmacist. Or report it directly to the TGA (Therapeutic Goods Administration).

You can report side effects to your doctor, or directly at Report an adverse event or safety problem (Opens in new tab)

Source: ARTG

Healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.

Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions (Opens in new tab).